Overconsumption of antibiotics
It is with great interest that I read the Article by Thomas Van Boeckel and colleagues, 1 reporting global antibiotic consumption. It is quite concerning that two-thirds of the increase in antibiotic usage between 2000 and 2010 occurred in BRICS countries (Brazil, Russia, India, China, and South Africa). As Van Boeckel and colleagues explain, this problem is partly due to the population increase in these countries, better access to drugs, and the improved socioeconomic status of BRICS countries. The absence of functioning antibiotic policies has fostered indiscriminate antibiotic use and misuse in most BRICS countries. The large increase in cephalosporin and fluoroquinolone consumption in India and China is particularly noteworthy, but is not unexpected as long as a course of these antibiotics is cheaper than a culture and sensitivity report. A large population size, socioeconomic disparity, and heterogeneity within the health-care system in most BRICS countries are major impediments for strict implementation of antibiotic policies.
Yet the highest use of antibiotics per person is in the USA, a country with good socioeconomic status that does not have the usual excuses for antibiotic misuse that developing countries have. The USA is also the country with the highest level of antibiotics misuse in veterinary practice.
2 Antibiotic usage in Australia and New Zealand has also increased over the same period. The publication of Van Boeckel and colleagues' Article coincided with a meeting between BRICS leaders in Brazil. If this coincidence was orchestrated with the good intention of mobilising political will in BRICS leaders, the authors should be congratulated. In the war against microbes, the end justifies the means. This is an opportunity for BRICS countries to consider the situation carefully. At the same time, the world should take an uncritical approach, as India did with the Chennai declaration. proposed by the Chennai declaration is an ideal template for the improvement of infection control and standard of antibiotic stewardship in developing countries. Even developed countries, such as the USA, might benefit from similar initiatives (eg, World Alliance against Antibiotic Resistance, Antibiotic Action, and ReAct) to reduce antibiotic usage in medical and veterinary practice.
I declare no competing interests. With the alarming increase in antimicrobial use worldwide, efforts are urgently needed to prevent un necessary antimicrobial consumption. Multidisciplinary groups should come together to promote the adoption and expansion of antimicrobial stewardship. Statewide collaboration focused on antimicrobial stewardship might be an effective means to improve utilisation of antimicrobials, which could be adopted by other states and regions worldwide. excellent saftey profile and without adverse effects. 4 Most of these trials (22 of 24) were done in high-income countries and in this setting probiotics had no significant effect on late-onset sepsis, a common complication of preterm birth, affecting up to 50% of the most immature infants (infants born before 28 weeks gestation; RR 0·91, 95% CI 0·80-1·03).
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4 By contrast, trials of probiotics done in resourcepoor and emerging settings show a significantly reduced incidence of bacterial and fungal late-onset sepsis in very low birthweight infants.
5-7 The benefits of probiotics in resource-poor settings are supported by a trial in a community setting in India in 2013 (n=4556), in which low birthweight infants (weighing >2000g) were given Lactobacillus plantarum and the prebiotic fructo-oligosaccharide, resulting in a significant reduction in serious infections (sepsis, pneumonia, and diarrhoea) during the first 60 days of life (personal communication).
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The reported reductions in lateonset sepsis caused by probiotic supplementation are probably affected by the gestational age and birthweight of the infants, the local pattern of invasive patho gens, the pathogen's antibiotic sus ceptibilities, and the type of probiotic strain or strains used.
In view of the global burden of preterm and very low birthweight infants with invasive infection and the increasing numbers of multidrugresistant microorganisms, probiotics have much potential in resourcepoor settings as a simple, safe, and affordable public health intervention. Additional research is essential to address the present gaps in knowledge on probiotics for treating preterm and low birthweight infants, especially in the context of resource poor settings. In view of the cost associated with the import, storage, and distribution of proven probiotic strains, future randomised controlled trials could compare the efficacy and safety of proven strains with that of local
Probiotics to prevent early-life infection
Anna Seale and colleagues 1 reported estimates of possible severe bacterial infec tion in neonates in resourcelimited settings. Worldwide about 15 million infants are born preterm each year and about 1 million of them die in infancy.
2 Additionally, roughly 18 million in fants are born with low birthweight, pre dominantly in low-income and middle-income countries. This population has a high burden of morbidity and mortality associated with invasive infections in the neonatal period and early infancy. THELANCETID-D-14-00955 S1473-3099(15)70088-5 LINKED TO: ND
